Key result
Targeting CD23 with anti-IgE:IgE complexes may inhibit macrophage fusion in giant cell myocarditis.
Why the study?
Existing combination immunosuppressive therapies for giant cell myocarditis lack precision and carry considerable adverse effects, motivating evaluation of CD23-targeted immunotherapy as a more selective and safer adjunctive treatment.
Does CD23-targeted immunotherapy with preformed anti-IgE:IgE complexes inhibit macrophage fusion, suppress pathogenic T-cell responses, and reduce myocardial injury in giant cell myocarditis?
Does CD23-targeted immunotherapy with preformed anti-IgE:IgE complexes inhibit macrophage fusion, suppress pathogenic T-cell responses, and reduce myocardial injury in giant cell myocarditis?
This hypothesis-generating review proposes CD23-engaging preformed anti-IgE:IgE complexes as a novel, selective candidate immunotherapy to inhibit macrophage fusion and attenuate T-cell-mediated myocardial injury in giant cell myocarditis, outlining a preclinical framework for experimental validation.
Proposed CD23 targeting with anti-IgE:IgE complexes merits preclinical testing in giant cell myocarditis; leaves open whether this selective strategy improves outcomes.
Giant cell myocarditis (GCM) is a rare, rapidly progressive cardiac disorder characterized by giant, multinucleated cells that contribute to severe myocardial damage. Existing combination immunosuppressive therapies, although directed at immune-mediated injury, lack precision and are associated with considerable adverse effects. A CD23-targeted intervention holds promise as a more selective, safer adjunctive treatment. This review evaluates a strategy centered on the low-affinity IgE receptor (CD23/FcεRII), predominantly expressed on alternatively activated (M2a) macrophages and B cells. The proposed method uses engineered anti-IgE–IgE complexes to engage CD23, inhibiting macrophage fusion—a defining feature of GCM—and fostering a more anti-inflammatory immune milieu. This therapy also aims to protect myocardial tissue by suppressing pathogenic T-cell responses and slowing disease progression. The review details the scientific basis for this approach, outlines laboratory testing protocols, suggests optimal delivery systems, and considers translational hurdles to clinical implementation.
No takes yet. Share an insight, caveat, or question.
Michael John Dochniak (2026) conducted a review in Giant cell myocarditis. Preformed anti-IgE:IgE complexes targeting CD23 (FcεRII) was evaluated. Preformed anti-IgE:IgE complexes targeting CD23 are proposed as a theoretical strategy to inhibit M2a macrophage fusion and dampen pathogenic T-cell responses in giant cell myocarditis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: